Assessment of Cost-Effectiveness of Treatment for Cardio-Cerebrovascular Diseases from Large-Sample Randomized Clinical Trials in China

王文,刘力生,龚兰生,张廷杰,吴宁

DOI: https://doi.org/10.3760/j:issn:0253-3758.2003.01.007

2003-01-01

Abstract:Objective To assess the cost effectiveness of treatment for cardio cerebrovascular diseases from large scale randomized clinical trials in China, and to recommend the effective and cost reasonable treatment to primary care clinicians Methods The criteria for study selection were as follows: completed large sample randomized controlled clinical trials on cardio cerebrovascular diseases ,which included more than 10 000 patients in acute trial and more than 500 patients in long term trial Study end points included death or serious vascular events Assessment index was focused on saving the number of lives or preventing the number of events per 1 000 treated patients, and the medicine expenses for preventing one event or saving one life Results Eight clinical trials were enrolled into the study, including China Systolic Hypertension Trial, Shanghai Trial of Nifedipine in the Elderly, Chengdu Hypertension Treatment Study, Post Stroke Antihypertensive Treatment Study in China, Chinese Cardiac Study I (CCS 1), Chinese Acute Stroke Trial, Protection Against Recurrent Stroke Study in China, Atenolol and Enalapril Secondary Prevention on Myocardial Infarction The analysis showed that calcium antagonist treatment could prevent 8-11 stroke events per 1 000 patients with hypertension Preventing one stroke needed about 2 400-10 000 yuan(RMB) Diuretic or ACE inhibitor treatment could prevent 11-23 stroke events each year per 1 000 patients with cerebrovascular diseases The drug expenses were about 23 000-80 000 yuan for preventing one stroke Atenolol or enalapril treatment could save 11 and 7 lives, respectively each year per 1 000 patients with myocardial infarction The drug expenses were about 2 000-40 000 yuan for saving one life ACE inhibitor captopril treatment could save 6 lives each month per 1 000 patients with acute myocardial infarction The drug expenses were about 30 000 yuan for saving one life Aspirin treatment could save 6 lives each month per 1 000 patients with acute ischemic stroke, and the drug expenses were only about 2 000 yuan for saving one life Conclusions It is effective and cost reasonable using calcium antagonist for treatment of hypertension, diuretics or ACE inhibitors for cerebrovascular diseases, captopril for acute myocardial infarction, atenolol or enalapril for myocardial infarction, and aspirin for acute ischemic stroke The evaluation can provide directive information for doctors′ clinical practice